High materiality7/10
Evommune price target lowered to $18 from $32 at Raymond James
Why it may matterVerify against the original reporting
Upside remains despite downgrade.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
EVMN received an analyst target update from Raymond James.
- Raymond James lowers EVMN target to $18; price now $11.12; upside persists.
Key facts
- 01
Target: $18
- 02
Posted price: $11.12
- 03
Analyst firm: Raymond James
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.